Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Xuanyan Xu

Solution Marketing Manager at Elsevier

Connect with Xuanyan Xu on LinkedIn
Follow Xuanyan Xu on Twitter
Website:

About the author: Xuanyan joined Elsevier in October 2016 and currently works as a solution marketing manager. She holds a master's degree in biochemistry and science-based business. Prior to Elsevier, she worked in QIAGEN and was involved in managing various parts of the life science portfolio. Xuanyan's interests span several emerging fields, particularly pharmacovigilance and systematic review researches.

Posts by Xuanyan Xu

Government Shutdown Means New Drugs May Have to Wait – But Safety Monitoring Will Continue

Posted on January 17th, 2019 in Pharma R&D

The partial shutdown of the U.S. government, which began just before the Christmas holiday, has been especially terrible for hundreds of thousands of federal employees who are either furloughed or working without pay. (more…)

FDA Announces Plans to Improve Approvals Process for Medical Devices

Posted on January 15th, 2019 in Pharma R&D

In the pharmaceutical industry, safety protocols are rigorous. Clinical trials, a lengthy and intense part of the drug development process, are deemed absolutely crucial to ensuring the safety and efficacy of new drugs and therapies. There are also many regulations designed to make certain that high standards are maintained during the various trial phases.

(more…)

In pharmacovigilance, effective search strings are key

Posted on February 9th, 2018 in Pharmacovigilance

A key component of any pharmacovigilance strategy is building search strings that successfully identify potential adverse events, which must be reported to regulatory agencies. If the query returns too narrow a result set, adverse events may be missed. (more…)

FDA Speeds Up Generic Approval Process

Posted on August 30th, 2017 in Pharmacovigilance

Healthcare has been in the spotlight for much of the year so far, as Congress has wrestled with the difficult question of how to make it both better and more affordable.

(more…)

  1. 1
  2. 2